GlaxoSmithKline and Theravance said the FDA has accepted their new drug application for Anoro as a daily treatment for chronic obstructive pulmonary disease. Anoro, formerly known as UMEC/VI, is a combination of umeclidinium bromide, a long-acting muscarinic antagonist, and vilanterol, a long-acting beta-2 agonist. The FDA is expected to decide by Dec. 18.
GSK and Theravance submit Anoro to FDA as COPD drug
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||